Navigation Links
NovaBay Pharmaceuticals Announces New Preclinical Data to be Presented at the American Academy of Dermatology (AAD) 67th Annual Meeting
Date:3/4/2009

Product Candidate NVC-422 Demonstrates Ability to Treat Subcutaneous Infections

EMERYVILLE, Calif., March 4 /PRNewswire-FirstCall/ -- NovaBay Pharmaceuticals, Inc. (NYSE Alternext: NBY), a clinical stage biopharmaceutical company, today announced that new preclinical data related to NVC-422, the lead molecule in NovaBay's, proprietary Aganocide(R) class of compounds, will be presented at the American Academy of Dermatology (AAD) 67th Annual Meeting in San Francisco during March 6-10, 2009. NovaBay is focused on developing first-in-class, novel, synthetic anti-infective product candidates that are bioequivalent to the active antimicrobial molecules generated within white blood cells for the treatment and prevention of bacterial, fungal, and viral infections without developing resistance.

"We have new data at the upcoming AAD annual meeting that further demonstrate the potential of NVC-422 and our Aganocide class of compounds to effectively treat chronic and common fungal skin infections," said Dr. Ron Najafi, chairman and chief executive officer. "Data from the Center for Medical Mycology at Case Western Reserve University Hospitals confirm how our novel, anti-infective agent in an animal model is highly effective not only on the skin surface, but also showed potent ability to kill subcutaneous organisms by route of the hair follicles."

Following are the details on the poster presentation.

    Saturday, March 7
    Poster Title: "Efficacy of NVC 422 in the Topical Treatment of
    Dermatophytosis in a Guinea Pig Model"
    Professor Mahmoud Ghannoum et al
    Time: 9:20 a.m. Pacific Time
    Moscone Center North, Hall E, Abstract #2405

About NVC-422

NVC-422 is the lead molecule in NovaBay's Aganocide class of compounds. NVC-422 is a non-antibiotic, stable analog of an anti-infective molecule produced by white blood cells. NovaBay believes that NVC-422 may deliver the same or better efficacy as currently used antibiotics without giving rise to resistant bacteria. In past in-vitro studies, NVC-422 has shown a broad therapeutic index with broad spectrum activity against bacteria of all types, including multidrug resistant species, shedding viruses including adenoviruses and herpes viruses, yeasts and fungi. In addition, NVC-422 has previously shown, in-vivo, to be safe at expected therapeutic doses in the nose, bladder, wounds and eye. NVC-422 is protected by U.S. Patent #7,462,361 until 2026. In addition to Alcon's development in the eye, NovaBay has taken NVC-422 into Phase II human trials for infections in the nose and bladder and expects to begin a Phase II trial for the treatment of skin infections, including those caused by MRSA (Methicillin resistant Staphylococcus aureus), in 2009.

About NovaBay Pharmaceuticals, Inc.

NovaBay Pharmaceuticals is a clinical stage biopharmaceutical company developing first-in-class, novel, synthetic anti-infective product candidates that are bioequivalent to the active antimicrobial molecules generated within white blood cells to treat and prevent a wide range of infections without developing resistance. NovaBay has entered into a licensing and research collaboration agreement with Alcon, Inc. for use of the Aganocide compounds in the eye, ear and sinus, and in contact lens solutions. NovaBay(R) and Aganocide(R) are trademarks of NovaBay Pharmaceuticals, Inc. For more information on NovaBay, visit www. novabaypharma.com.

Cautionary Information Regarding Forward-Looking Statements

The statements in this press release regarding the potential efficacy of NVC-422 and NovaBay's expectation to begin a Phase II trial for the treatment of skin infections in 2009 are forward-looking statements. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected in these forward-looking statements. These risks and uncertainties include, among others, the risk that results obtained in animal models may not be obtained in humans, and the risk of unexpected delays in the regulatory process may delay the commencement or completion of clinical trials. Other risks relating to NovaBay and NVC-422, including risks that could cause actual results to differ materially from those projected in the forward-looking statements in this press release, are detailed in NovaBay's Quarterly Report on Form 10-Q/A for the period ended September 30, 2008, under the caption "Risk Factors" in Item 1A of Part II of that report, which was filed with the Securities and Exchange Commission on November 14, 2008.


'/>"/>
SOURCE NovaBay Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. NovaBay Pharmaceuticals Closes Initial Public Offering of Common Stock
2. NovaBay announces third quarter 2007 financial results
3. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
4. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
5. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
6. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
7. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
8. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
9. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
10. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
11. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... (PRWEB) , ... February 23, 2017 , ... ... a new partnership with the Rhode Island Consortium for Autism Research and Treatment ... opportunity for children with autism spectrum disorder (ASD) to see films in an ...
(Date:2/23/2017)... ... 2017 , ... Curemark, LLC announced today that the Blüm Study, a Phase ... 3-8 with Autism, is now enrolling at three new sites. These new sites are ... , “There are currently no approved drugs that address the core symptoms of ...
(Date:2/22/2017)... ... February 22, 2017 , ... When ... new healthcare contact center in Georgia, PENETRON Specialty Products (PSP) provided the solution. ... healthcare systems recently invested $51 million to purchase and renovate the 185,000 square-foot ...
(Date:2/22/2017)... Angeles, CA (PRWEB) , ... February 22, 2017 , ... ... detox treatment to the thousands of individuals who have recently fallen victim to America’s ... hospital in Orange County, California, where they are free from the shame, stigma, ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... leads to fewer trips the emergency room, fewer hospital admissions, and better blood ... of Managed Care® (AJMC®) finds. The study can be found here . ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... , Feb. 23, 2017   SeraCare Life ... global in vitro diagnostics manufacturers and clinical laboratories, ... "Catalyzing Implementation of NGS-Based Tests" to be hosted ... 2017 at 11am Eastern Standard Time (US). ... highlight the need for improved performance and global ...
(Date:2/23/2017)... -- ML Capital Group, Inc. (USOTC: MLCG) today announced ... , a Colorado -based cannabis tourism company. ... (USOTC: PURA) to enter Colorado,s $19 billion ... Tours acquisition announced today is intended to accelerate MLCG,s ... ...
(Date:2/23/2017)... DIEGO , Feb. 23, 2017 ... a clinical-stage oncology drug development company, announces that ... and Drug Administration (FDA) authorizing the initiation a ... therapeutic treatment for pancreatic cancer. MVT-1075 ( 177 ... radioimmunotherapy (RIT). MabVax plans to initiate the phase ...
Breaking Medicine Technology: